Related Experiment Video
Updated: Dec 14, 2025
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Growth factor therapy for cardiac repair: an overview of recent advances and future directions
Samuel J White1, James J H Chong2,3
1Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.
Insights
New growth factors like IGF-1 and neuregulin show promise for repairing heart damage, offering functional improvement in early trials. Further research is needed to overcome delivery challenges for effective cardiac regeneration therapies.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Molecular Cardiology
Background:
- Heart disease causes significant morbidity and mortality.
- Current therapies fail to fully restore function after cardiac injury.
- Understanding endogenous repair mechanisms is key.
Purpose of the Study:
- To explore novel therapeutic approaches for cardiac repair and regeneration.
- To investigate the potential of specific growth factors as agents for cardiac pathology.
- To address limitations in current regenerative strategies for heart disease.
Main Methods:
- Investigating the role of growth factors in endogenous cardiac repair.
- Evaluating insulin-like growth factor 1 (IGF-1), neuregulin, and platelet-derived growth factor (PDGF) as therapeutic candidates.
- Analyzing preclinical and early human trial data for efficacy and safety.
Main Results:
- IGF-1, neuregulin, and PDGF demonstrate tissue repair through anti-apoptotic, pro-angiogenic, and fibrosis-modulating mechanisms.
- These growth factors have shown clinically significant functional improvement in preclinical studies.
- Early human trials indicate IGF-1 and neuregulin are well-tolerated and provide dose-dependent benefits.
Conclusions:
- IGF-1 and neuregulin show therapeutic potential for heart disease, warranting further clinical investigation.
- Growth factors offer promising avenues for repairing damaged cardiac tissue.
- Novel delivery strategies are required to address challenges like short serum half-life and target-organ specificity.
Abstract:
Heart disease represents a significant public health burden and is associated with considerable morbidity and mortality at the level of the individual. Current therapies for pathologies such as myocardial infarction, cardiomyopathy and heart failure are unable to repair damaged tissue to an extent that provides restoration of function approaching that of the pre-diseased state. Novel approaches to repair and regenerate the injured heart include cell therapy and the use of exogenous factors. Improved understanding of the role of growth factors in endogenous cardiac repair processes has motivated the investigation of their potential as therapeutic agents for cardiac pathology. Despite the disappointing performance of other growth factors in historical clinical trials, insulin-like growth factor 1 (IGF-1), neuregulin and platelet-derived growth factor (PDGF) have recently emerged as new candidate therapies. These growth factors elicit tissue repair through anti-apoptotic, pro-angiogenic and fibrosis-modulating mechanisms and have produced clinically significant functional improvement in preclinical studies. Early human trials suggest that IGF-1 and neuregulin are well tolerated and yield dose-dependent benefit, warranting progression to later phase studies. However, outstanding challenges such as short growth factor serum half-life and insufficient target-organ specificity currently necessitate the development of novel delivery strategies.
